Skip to main content
    I

    InfuSystems Holdings Inc (INFU)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX

    $14.81
    +0.09 (+0.61%)

    Market Cap: $294.89M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    InfuSystems Holdings Inc (INFU) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    InfuSystems Holdings (INFU) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, InfuSystems Holdings reported EPS of $0.20, above the $0.12 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    52%(14/27)
    Avg Surprise
    +72.67%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.16
    Range$0.13 - $0.18
    5 analysts
    Revenue Consensus
    $39.04M
    Range$36.65M - $42.00M
    5 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.07
    Range$0.07 - $0.07
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.05+40.0%
    7d ago$0.05+40.0%
    Current$0.07
    Revenue Consensus
    $35.34M
    Range$34.51M - $36.50M
    3 analysts

    Next Report

    INFU has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 60.0% above the $0.10 reported for the quarter ended Dec 31, 2025.

    INFU Earnings Call

    The latest INFU earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 27 quarters below that had an estimate, INFU beat 14, missed 11 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $37.59M, up 3.0% from $36.49M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.20$0.12$0.12 - $0.12+66.67%Beat+33.3%11 up, 0 downNov 5, 2026$37.59M
    Jun 30, 2026$0.15$0.12$0.09 - $0.12+25.00%Beat0.0%40 up, 1 downAug 4, 2026$36.93M
    Mar 31, 2026$0.05$0.03-$0.01 - $0.06+66.67%Beat-50.0%52 up, 2 downMay 7, 2026$33.68M
    Dec 31, 2025$0.10$0.07$0.05 - $0.11+42.86%Beat+41.8%51 up, 0 downFeb 24, 2026$36.23M
    Sep 30, 2025$0.15$0.05$0.05 - $0.05+200.00%Beat+15.4%11 up, 0 downNov 4, 2025$36.49M
    Jun 30, 2025$0.15$0.04$0.04 - $0.04+275.00%Beat+400.0%10 up, 1 downAug 5, 2025$36.00M
    Mar 31, 2025$0.10-$0.03-$0.03 - -$0.03+433.33%BeatN/A10 up, 1 downMay 8, 2025$34.72M
    Dec 31, 2024$0.07$0.06$0.06 - $0.06+17.50%Beat+2036.4%10 up, 1 downMar 4, 2025$33.85M
    Sep 30, 2024$0.13$0.05$0.05 - $0.08+160.00%Beat+85.7%40 up, 0 downNov 7, 2024$35.32M
    Jun 30, 2024$0.03$0.04$0.03 - $0.04-25.00%Miss0.0%30 up, 0 downAug 8, 2024$33.70M
    Mar 31, 2024-$0.05$0.01-$0.01 - $0.05-600.00%MissN/A30 up, 0 downMay 9, 2024$32.00M
    Dec 31, 2023$0.00$0.02-$0.02 - $0.02-83.50%Miss-67.0%20 up, 0 downMar 14, 2024$31.77M
    Sep 30, 2023$0.07$0.09N/A-22.22%Miss+133.3%30 up, 0 downNov 7, 2023$31.91M
    Jun 30, 2023$0.03$0.08N/A-62.50%MissN/A30 up, 0 downAug 3, 2023$31.73M
    Mar 31, 2023-$0.01$0.06N/A-116.67%MissN/A30 up, 0 downMay 4, 2023$30.37M
    Dec 31, 2022$0.01$0.04$0.03 - $0.06-75.00%Miss-50.0%31 up, 0 downMar 15, 2023$28.83M
    Sep 30, 2022$0.03$0.01-$0.01 - $0.02+200.00%BeatN/A30 up, 0 downNov 8, 2022$27.28M
    Jun 30, 2022-$0.01-$0.01-$0.03 - $0.010.00%In line-120.0%30 up, 0 downAug 4, 2022$27.04M
    Mar 31, 2022-$0.02-$0.03-$0.05 - $0.00+33.33%Beat-166.7%30 up, 0 downMay 5, 2022$26.76M
    Dec 31, 2021$0.02$0.07$0.00 - $0.14-71.43%Miss-95.9%4N/AFeb 10, 2022$26.52M
    Sep 30, 2021-$0.02$0.01-$0.02 - $0.06-300.00%Miss-114.3%40 up, 0 downNov 15, 2021$26.57M
    Jun 30, 2021$0.05$0.07$0.04 - $0.13-28.57%Miss-75.0%4N/AAug 12, 2021$24.83M
    Mar 31, 2021$0.03$0.05$0.02 - $0.06-40.00%MissN/A4N/AMay 6, 2021$24.46M
    Dec 31, 2020$0.49$0.06$0.03 - $0.08+716.67%Beat+1125.0%3N/AMar 17, 2021$24.71M
    Sep 30, 2020$0.14$0.04$0.02 - $0.05+250.00%Beat+180.0%2N/ANov 12, 2020$25.13M
    Jun 30, 2020$0.20$0.02$0.02 - $0.02+900.00%Beat+900.0%1N/AAug 13, 2020$26.00M
    Mar 31, 2020-$0.02-$0.02N/A0.00%In lineN/AN/AN/AMay 14, 2020$21.55M
    Dec 31, 2019$0.04N/AN/AN/AN/AN/AN/AN/AMar 19, 2020$21.71M
    Sep 30, 2019$0.05N/AN/AN/AN/AN/AN/AN/ANov 13, 2019$21.49M
    Jun 30, 2019$0.02N/AN/AN/AN/AN/AN/AN/AAug 14, 2019$19.72M
    Mar 31, 2019-$0.05N/AN/AN/AN/A-600.0%N/AN/AMay 14, 2019$18.19M
    Dec 31, 2018-$0.01N/AN/AN/AN/AN/AN/AN/AMar 7, 2019$17.56M
    Sep 30, 2018-$0.03N/AN/AN/AN/AN/AN/AN/ANov 13, 2018$16.68M
    Jun 30, 2018-$0.02N/AN/AN/AN/AN/AN/AN/AAug 14, 2018$16.41M
    Mar 31, 2018$0.01N/AN/AN/AN/AN/AN/AN/AApr 24, 2018$16.48M
    Dec 31, 2017-$0.04N/AN/AN/AN/AN/AN/AN/AMar 13, 2018$18.89M
    Sep 30, 2017-$0.01N/AN/AN/AN/A-516.7%N/AN/ANov 10, 2017$17.59M
    Jun 30, 2017-$0.05N/AN/AN/AN/A-857.6%N/AN/AAug 9, 2017$16.94M
    Mar 31, 2017-$0.07N/AN/AN/AN/A-3988.9%N/AN/AMay 11, 2017$17.65M
    Dec 31, 2016-$0.02N/AN/AN/AN/A-123.9%N/AN/AMar 22, 2017$16.85M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.50, up 177.0% from the year before. It was -$0.01 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.50+177.0%
    Dec 31, 2024$0.18+93.5%
    Dec 31, 2023$0.09+833.0%
    Dec 31, 2022$0.01-87.5%
    Dec 31, 2021$0.08-90.1%
    Dec 31, 2020$0.81+1250.0%
    Dec 31, 2019$0.06N/A
    Dec 31, 2018-$0.05N/A
    Dec 31, 2017-$0.17N/A
    Dec 31, 2016-$0.01N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 4,000 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20264,0048
    2025Q4Dec 31, 20253,8989
    2025Q3Sep 30, 20254,3908
    2025Q2Jun 30, 20254,4598
    2025Q1Mar 31, 20254,6059
    2024Q4Dec 31, 20245,1809
    2024Q3Sep 30, 20245,71210
    2024Q2Jun 30, 20244,5708

    2026Q1 Earnings Call

    Opening remarks

    Glen Akselrod Investor Relations Good morning, and thank you for joining us today to review InfuSystem's First Quarter 2026 Financial Results ended March 31, 2026. With us today on the call are Carrie Lachance, Chief Executive Officer; and Barry Steele, Chief Financial Officer. After the conclusion of today's prepared remarks, we will open the call for questions. Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of InfuSystem during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under the Risk Factors in the documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2025. Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. InfuSystem does not undertake and specifically disclaims any obligation to update any forward-looking statements, except as required by law. Now I'd like to turn the call over to Carrie Lachance, Chief Executive Officer of InfuSystem. Carrie?

    Carrie Lachance Chief Executive Officer Thank you, Glen, and good morning, everyone. Welcome to InfuSystem's First Quarter Fiscal Year 2026 Earnings Call. Thank you all for joining us today. I will provide a first quarter overview, highlighting key initiatives and updating our progress on strategic priorities. Then Barry will provide a detailed summary of our financial results. I will then come back with some closing comments before opening the line to questions. Today, we reported first quarter of 2026 revenue of $33.7 million. This represented a decline from our prior year of just over $1 million on a GAAP basis, but a 1.7% increase on a pro forma basis. The GAAP reduction was mainly driven by the restructuring of our biomedical services contract with GE Healthcare, which reduced revenue by $1.6 million during the first quarter and is the basis for the adjustment to provide pro forma revenue. As we reported on our last two earnings calls, this restructuring improves our earnings because it allowed for an even larger reduction in direct contract expenses. Despite the decline in revenue, we generated approximately $6.4 million in adjusted EBITDA this quarter, roughly in line with the prior year, resulting in a modest improvement in adjusted EBITDA margin to 18.9%, up from 18.2% in the first quarter last year. Behind these results are two very important initiatives that warrant the progress update. First, we continue to expand our wound care product category.

    Frequently Asked Questions About INFU

    When is InfuSystems Holdings's next earnings date?

    InfuSystems Holdings's next earnings report is expected for Feb 22, 2027.

    Did INFU beat earnings estimates last quarter?

    Yes. InfuSystems Holdings reported EPS of $0.20 for the quarter ended Sep 30, 2026, above the $0.12 estimate, a 66.67% surprise.

    What EPS do analysts expect from INFU next quarter?

    The consensus EPS estimate for InfuSystems Holdings for the quarter ending Dec 31, 2026 is $0.16 from 5 analysts, with estimates from $0.13 to $0.18.

    How often does INFU beat earnings estimates?

    InfuSystems Holdings beat the EPS estimate in each of the last 9 quarters, with an average surprise of +143.00%.